CoChat

Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E 2 –Dependent Matrix Metalloproteinase Activity

Open access
Cipollone, Francesco, Fazia, Maria, Iezzi, Annalisa, Pini, Barbara, Cuccurullo, Chiara, Zucchelli, Mirco, de Cesare, Domenico, Ucchino, Sante, Spigonardo, Francesco, De Luca, Mariella, Muraro, Raffaella, Bei, Roberto, Bucci, Marco, Cuccurullo, Franco, Mezzetti, Andrea · 2004 · Circulation
Cited by 138

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background— Clinical trials have demonstrated that agents that inhibit the angiotensin II pathway confer benefit beyond the reduction of blood pressure alone. However, the molecular mechanism underlying this effect has yet to be investigated. Recently, we have demonstrated enhanced expression of inducible cyclooxygenase (COX) and prostaglandin (PG)E 2 -dependent synthase (COX-2/mPGES-1) in human symptomatic plaques and provided evidence that it is associated with metalloproteinase (MMP)-induced plaque rupture. Thus, the aim of this study was to characterize the effect of the angiotensin II type 1 (AT 1 ) receptor antagonist irbesartan on the inflammatory infiltration and expression of COX-2/mPGES-1 and MMPs in human carotid plaques. Methods and Results— Seventy patients with symptomatic carotid artery stenosis were randomized to irbesartan (300 mg/d) or chlorthalidone (50 mg/d) for 4 months before endarterectomy. Plaques were subjected to analysis of COX-1, COX-2, mPGES-1, MMP-2, and MMP-9, angiotensin II, AT 1 , AT 2 , and collagen content by immunocytochemistry, Western blot, and reverse-transcriptase polymerase chain reaction, whereas zymography was used to detect MMP activity. Immunohistochemistry was also used to identify CD68+ macrophages, CD3+ T lymphocytes, smooth muscle cells (SMCs), and HLA-DR+ inflammatory cells. Plaques from the irbesartan group had fewer ( P <0.0001) macrophages, T lymphocytes, and HLA-DR+ cells; less ( P <0.0001) immunoreactivity for COX-2/mPGES-1 and MMPs; reduced ( P <0.0001) gelatinolytic activity; and increased ( P <0.0001) collagen content. It is worth noting that COX-2/mPGES-1 inhibition was observed after incubation in vitro with irbesartan but not with the selective AT 2 blockade PD123,319. Conclusions— This study demonstrates that irbesartan decreases inflammation and inhibits COX-2/mPGES-1 expression in plaque macrophages, and this effect may in turn contribute to plaque stabilization by inhibition of MMP-induced plaque rupture.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/01.cir.0000121735.52471.ac

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 138

Metadata

Authors
Cipollone, F., Fazia, M., Iezzi, A., Pini, B., Cuccurullo, C., Zucchelli, M., de Cesare, D., Ucchino, S., Spigonardo, F., De Luca, M., Muraro, R., Bei, R., Bucci, M., Cuccurullo, F., & Mezzetti, A.
Venue
Circulation
Published
2004-03-30
Volume
109
Issue
12
Pages
1482-1488
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2161942310
Cited by
138
References
4
FWCI
14.31
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E 2 –Dependent Matrix Metalloproteinase Activity. https://app.cochat.ai/papers/10.1161/01.cir.0000121735.52471.ac
The paper
Cipollone, F., Fazia, M., Iezzi, A., Pini, B., Cuccurullo, C., Zucchelli, M., de Cesare, D., Ucchino, S., Spigonardo, F., De Luca, M., Muraro, R., Bei, R., Bucci, M., Cuccurullo, F., & Mezzetti, A. (2004). Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E 2 –Dependent Matrix Metalloproteinase Activity. Circulation. https://doi.org/10.1161/01.cir.0000121735.52471.ac

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.